Aduhelm Looks Set For Rejection In Europe For Alzheimer's
Adds To US Woes
Executive Summary
The EMA’s likely rejection is no surprise for Biogen and Eisai, but adds to problems in the same week as Biogen’s R&D leader announced his departure.
You may also be interested in...
Aducanumab: Biogen Is The Latest Firm To Preempt A Negative EU Opinion On Approval
The EU marketing application for aducanumab is heading for a rejection for Alzheimer’s disease, according to a “negative trend vote” at the CHMP disclosed by the drug’s sponsors.
The Architect Of Biogen's Controversial Alzheimer's Strategy, Al Sandrock, To Retire
Despite 23 years at Biogen assisting in the development of several drugs, Sandrock's legacy will be tied to Alzheimer’s drug Aduhelm.
Biogen’s Q3 Aduhelm Sales Even Worse Than Expected
Analysts expected at least $12m in third quarter sales, but the Alzheimer’s therapy brought in just $300,000. The company says educating doctors and procuring a coverage determination from CMS – not lower pricing – are key to growth.